Leqembi™ (lecanemab-irmb) for Alzheimer’s disease – New drug approval
January 6, 2023 - The FDA announced the approval of Eisai and Biogen’s Leqembi (lecanemab-irmb), for the treatment of Alzheimer’s disease (AD). Treatment with Leqembi should be initiated in patients with mild cognitive impairment or mild dementia stage of disease, the population in which treatment was initiated in clinical trials. There are no safety or effectiveness data on initiating treatment at earlier or later stages of the disease than were studied.
Top